0 258

Cited 0 times in

Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이현웅-
dc.contributor.author한광협-
dc.contributor.author현혜경-
dc.date.accessioned2021-09-29T01:13:15Z-
dc.date.available2021-09-29T01:13:15Z-
dc.date.issued2021-07-
dc.identifier.issn0163-2116-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184253-
dc.description.abstractBackground and aims: The influence of direct-acting antivirals (DAAs) on chronic hepatitis C (CHC)-related hepatocellular carcinoma (HCC) remains controversial. We investigated the effect of eradicating CHC using DAAs on treatment outcomes in patients with CHC-related HCC treated with transarterial chemoembolization (TACE). Methods: This nationwide, multi-center, retrospective study recruited patients with CHC-related HCC treated with TACE as the first-line anti-cancer treatment, and who achieved a sustained virological response (SVR) using DAAs (DAA group) between 2006 and 2017. Patients achieving an SVR following interferon-based treatment (IFN group) and those without treatment (control group) were also recruited for comparison. Results: A total of 425 patients were eligible for the study. Of these, 356 (83.8%), 26 (6.1%), and 43 (10.1%) were allocated to the control, IFN, and DAA groups, respectively. A multivariate analysis showed that liver cirrhosis, segmental portal vein thrombosis, and larger maximal tumor size independently predicted an increased risk of progression (all p < 0.05), whereas, the DAA group (vs. IFN and control groups) independently predicted a reduced risk of progression (hazard ratio (HR) = 0.630, 95% confidence interval 0.411-0.966, p = 0.034). The cumulative incidence rate of HCC progression in the DAA group was significantly lower than that in the IFN and control groups (p = 0.033, log-rank test). In addition, the DAA group (vs. IFN and control groups) was independently associated with a reduced risk of mortality (p = 0.042). Conclusions: DAA treatment provided significantly prolonged progression-free survival in patients with CHC-related HCC treated with TACE compared to that in patients administered IFN or no treatment.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer Science + Business Media-
dc.relation.isPartOfDIGESTIVE DISEASES AND SCIENCES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleDirect-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHye Kyung Hyun-
dc.contributor.googleauthorEun Ju Cho-
dc.contributor.googleauthorSoo Young Park-
dc.contributor.googleauthorYoung Mi Hong-
dc.contributor.googleauthorSoon Sun Kim-
dc.contributor.googleauthorHwi Young Kim-
dc.contributor.googleauthorNae-Yun Heo-
dc.contributor.googleauthorJung Gil Park-
dc.contributor.googleauthorDong Hyun Sinn-
dc.contributor.googleauthorWonseok Kang-
dc.contributor.googleauthorSong Won Jeong-
dc.contributor.googleauthorMyeong Jun Song-
dc.contributor.googleauthorHana Park-
dc.contributor.googleauthorDanbi Lee-
dc.contributor.googleauthorYong Sun Lee-
dc.contributor.googleauthorSung Bum Cho-
dc.contributor.googleauthorChan Sik An-
dc.contributor.googleauthorHyung Jin Rhee-
dc.contributor.googleauthorHyun Woong Lee-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorJeong-Hoon Lee-
dc.contributor.googleauthorSu Jong Yu-
dc.contributor.googleauthorYoon Jun Kim-
dc.contributor.googleauthorJung-Hwan Yoon-
dc.contributor.googleauthorWon Young Tak-
dc.contributor.googleauthorYoung Oh Kweon-
dc.contributor.googleauthorKi Tae Yoon-
dc.contributor.googleauthorMong Cho-
dc.contributor.googleauthorJae Youn Cheong-
dc.contributor.googleauthorSeung Ha Park-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.1007/s10620-020-06533-7-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA03292-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00737-
dc.identifier.eissn1573-2568-
dc.identifier.pmid32856240-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs10620-020-06533-7-
dc.subject.keywordDirect-acting antiviral-
dc.subject.keywordHepatitis C virus-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordProgression-
dc.subject.keywordTransarterial chemoembolization-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이현웅-
dc.contributor.affiliatedAuthor한광협-
dc.citation.volume66-
dc.citation.number7-
dc.citation.startPage2427-
dc.citation.endPage2438-
dc.identifier.bibliographicCitationDIGESTIVE DISEASES AND SCIENCES, Vol.66(7) : 2427-2438, 2021-07-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.